1. Home
  2. RYTM vs MPW Comparison

RYTM vs MPW Comparison

Compare RYTM & MPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • MPW
  • Stock Information
  • Founded
  • RYTM 2008
  • MPW 2003
  • Country
  • RYTM United States
  • MPW United States
  • Employees
  • RYTM N/A
  • MPW N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • MPW Real Estate Investment Trusts
  • Sector
  • RYTM Health Care
  • MPW Real Estate
  • Exchange
  • RYTM Nasdaq
  • MPW Nasdaq
  • Market Cap
  • RYTM 3.2B
  • MPW 3.5B
  • IPO Year
  • RYTM 2017
  • MPW 2005
  • Fundamental
  • Price
  • RYTM $52.70
  • MPW $6.01
  • Analyst Decision
  • RYTM Strong Buy
  • MPW Hold
  • Analyst Count
  • RYTM 12
  • MPW 7
  • Target Price
  • RYTM $68.58
  • MPW $5.64
  • AVG Volume (30 Days)
  • RYTM 544.5K
  • MPW 11.4M
  • Earning Date
  • RYTM 05-06-2025
  • MPW 05-08-2025
  • Dividend Yield
  • RYTM N/A
  • MPW 5.30%
  • EPS Growth
  • RYTM N/A
  • MPW N/A
  • EPS
  • RYTM N/A
  • MPW N/A
  • Revenue
  • RYTM $130,126,000.00
  • MPW $1,038,695,000.00
  • Revenue This Year
  • RYTM $47.06
  • MPW N/A
  • Revenue Next Year
  • RYTM $68.10
  • MPW $6.96
  • P/E Ratio
  • RYTM N/A
  • MPW N/A
  • Revenue Growth
  • RYTM 68.06
  • MPW 17.27
  • 52 Week Low
  • RYTM $35.17
  • MPW $3.51
  • 52 Week High
  • RYTM $68.58
  • MPW $6.55
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 48.00
  • MPW 60.47
  • Support Level
  • RYTM $52.54
  • MPW $6.06
  • Resistance Level
  • RYTM $55.21
  • MPW $6.28
  • Average True Range (ATR)
  • RYTM 2.05
  • MPW 0.20
  • MACD
  • RYTM 0.36
  • MPW -0.03
  • Stochastic Oscillator
  • RYTM 47.82
  • MPW 58.90

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About MPW Medical Properties Trust Inc. common stock

Medical Properties Trust Inc is a healthcare facility REIT. The company operates one segment, which owns and leases healthcare facilities. The vast majority of Medical's revenue is generated in the United States, followed by Germany and the United Kingdom. It provides financing for a variety of facilities that require funds for acquisitions, sale-leasebacks, new developments, and expansion projects.

Share on Social Networks: